A Novel Compound ARN-3236 Inhibits Salt-Inducible Kinase 2 and Sensitizes Ovarian Cancer Cell Lines and Xenografts to Paclitaxel
Jinhua Zhou(Yunnan Academy of Agricultural Sciences), Robert C. Bast(The University of Texas MD Anderson Cancer Center), Janice M. Santiago‐O’Farrill(The University of Texas MD Anderson Cancer Center), Abdulkhaliq Alsaadi(University of Oxford), Hiroshi Takemori(Gifu University), Venkata Krishna Yerramreddy Reddy(Arrien Pharmaceuticals (United States)), Albandri Alfraidi(Imperial College London), Ahmed A. Ahmed(St. George's University), Hariprasad Vankayalapati(University of Utah), Zhen Lü(The University of Texas MD Anderson Cancer Center), Yan Wang(The University of Texas MD Anderson Cancer Center), Shu Zhang(Tianjin University of Technology), Jinsong Liu(Guangzhou Institutes of Biomedicine and Health), Hailing Yang(The University of Texas MD Anderson Cancer Center), Weiqun Mao(The University of Texas MD Anderson Cancer Center)
Cited by 77
Related Papers
Guidelines and definitions for research on epithelial–mesenchymal transition
|Nature Reviews Molecular Cell Biology|2020|2.3k
Reactivity of a monoclonal antibody with human ovarian carcinoma.
|Journal of Clinical Investigation|1981|1.7k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k